Comparison of the Effects of Pioglitazone and Metformin on Insulin Resistance and Hormonal Markers in Patients with Impaired Glucose Tolerance and Early Diabetes

Eguchi, Kazuo; Tomizawa, Hidenori; Ishikawa, Joji; Hoshide, Satoshi; Numao, Toshio; Fukuda, Toshio; Shimada, Kazuyuki

doi:10.1291/hypres.30.23

Cited by 36 publications

(20 citation statements)

References 44 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recently published analysis of the Diabetes Prevention Program could demonstrate that lifestyle interventions and metformin reduced the development of a metabolic syndrome in high-risk patients [66] . Glitazones are antidiabetic drugs which improve insulin sensitivity through a reduction in muscle lipid content and re-distribution of lipid into adipose tissue [67] . Caution is indicated in elderly patients with respect to data about an increased rate of heart failure and an increase in bone fractures in elderly women under glitazone therapy.…”

Section: Metabolic Syndrome and Type 2 Diabetesmentioning

confidence: 99%

Obesity and the Metabolic Syndrome in the Elderly – A Mini-Review

Lechleitner

2008

Gerontology

View full text Add to dashboard Cite

The metabolic syndrome is defined as a cluster of cardiometabolic risk factors which are related to insulin resistance. Beyond the importance of each separate risk factor, the aggregation of abdominal obesity, impaired glucose metabolism, dyslipidemia and hypertension, summarized as the metabolic syndrome, characterizes individuals with a significant increase in the risk for type 2 diabetes and cardiovascular disease. In the prosperous countries of the world, the prevalence of the metabolic syndrome is about 20% in the adult population, and increases with increasing age, which is mainly attributed to the significant increase in overweight and obesity, also in elderly. Current data indicate that weight-loss therapy improves physical function, quality of life and the medical complications associated with obesity. This review summarizes epidemiologic data, diagnostic criteria and the clinical importance of the metabolic syndrome, the complex pathophysiologic mechanisms involved in the development of insulin resistance in elderly, and the various therapeutic options. According to these data the identification and treatment of patients with a metabolic syndrome would be an important approach to reduce morbidity and impairments in the elderly.

show abstract

Section: Metabolic Syndrome and Type 2 Diabetesmentioning

confidence: 99%

Obesity and the Metabolic Syndrome in the Elderly – A Mini-Review

Lechleitner

2008

Gerontology

View full text Add to dashboard Cite

show abstract

“…Several studies have reported that antihyperlipidemic agents [41][42][43][44] , angiotensin receptor blockade therapy [45][46][47] , and thiazolidinedines 13,14) significantly increase both s-LpL and blood adiponectin concentrations. These drugs have been confirmed to be clinically useful for preventing primary and secondary cardiac events [48][49][50] ; thus, it is possible that these protective effects towards coronary vessels are caused by increased s-LpL or blood adiponectin concentrations.…”

Section: Discussionmentioning

confidence: 99%

“…Coronary risk factors, including s-LpL and serum adiponectin concentrations, were compared. It is well known that thiazolidinedines powerfully increase both lipoprotein lipase and adiponectin concentrations in blood 13,14) ; therefore, we excluded subjects with thiazolidinedines use in this study. All subjects gave their written informed consent and the study protocol was approved by the local ethics committee.…”

Section: Subjectsmentioning

confidence: 99%

Relationship between Two AMI Risk Factors: Low Serum Lipoprotein Lipase Mass and Hypoadiponectinemia

Hatori

Takahashi

Iizuka

et al. 2011

JAT

View full text Add to dashboard Cite

Aim: Recent clinical studies have reported that low lipoprotein lipase mass in preheparin serum (s-LpL) and hypoadiponectinemia are important risk factors for acute myocardial infarction (AMI). The aim of this study was to elucidate the relationship between low s-LpL and hypoadiponectinemia, both of which are risk factors for AMI. Methods: One hundred and thirty-seven male patients with AMI and fifty-three males with normal coronary arteries (NCA) were enrolled in the study. Coronary risk factors, including s-LpL and serum total adiponectin concentrations (t-adiponectin), were compared. Results: Both s-LpL and t-adiponectin were significantly lower in patients with AMI than in subjects with NCA (s-LpL, NCA: 48.1 11.0 ng/mL, AMI: 38.9 11.1 ng/mL, p 0.01; t-adiponectin, NCA: 7.7 2.9 g/mL, AMI: 6.

show abstract

“…In patients with type 2 diabetes or other insulin-resistant conditions, TZD treatment typically produces a doubling of plasma adiponectin concentration ( 17,(73)(74)(75). In contrast, other antidiabetic or lipid-modifying drugs produce much smaller or no changes in adiponectin (76)(77)(78)(79). In parallel with increased adiponectin production by adipose tissue, activation of PPAR-␥ in adipocytes or in mononuclear infl ammatory cells resident in adipose tissue reduces local infl ammation and inhibits release of infl ammatory mediators from adipose tissue (80)(81)(82)(83).…”

Section: Adiponectinmentioning

confidence: 99%